Sugar rising after breakfast
Can Tirzepatide add to the help from gut hormone GLP-1?
A high reading after breakfast can be frustrating despite your care. The body may release too little insulin, or use insulin poorly. Researchers tested changes in both jobs.
Why is low sugar less likely with this drug alone?
Breakfast can raise blood sugar even when you've watched what you eat. GIP and GLP-1 are gut hormones that help release insulin after food. Insulin brings sugar down, and tirzepatide copies those hormone actions. As sugar falls, the push to release more insulin weakens.
That makes dangerously low sugar uncommon when tirzepatide is used alone. Medicines copying GLP-1 alone use the same sugar-dependent action. Tirzepatide adds help through another gut hormone as well. Your other diabetes medicines can still raise the chance of low sugar.
Early findings came from cells grown in lab dishes, rather than people. GIP action was stronger with tirzepatide than GLP-1 action [2]. Its GLP-1 action also kept insulin-making cells able to respond for longer through GLP-1. Researchers think both differences may help explain the later trial benefits.
The clearest human insulin test was a small 117-person study. Researchers checked insulin release and how effectively insulin brought sugar down. Both insulin jobs improved together more on tirzepatide than on the comparison medicine [8]. That's support from people, although the small study can't settle your treatment choice.
What did Tirzepatide change in cells grown in lab dishes?
Willard's 2020 work tested cells and insulin-making tissue, not patient weight loss. GIP and GLP-1 are gut hormones that encourage insulin release. The tests asked how tirzepatide copied GIP and GLP-1 action. Researchers described several differences that might explain the human findings [2].
- Which hormone action was stronger? The drug acted more strongly through GIP than through GLP-1. Copying the two hormones didn't mean equal strength through each. A medicine copying GLP-1 alone lacks that added hormone action.
- Why might cells keep releasing insulin longer? GLP-1 works through a receptor, the cell part that responds to this hormone. The cell normally pulls that part from the surface to the inside. Tirzepatide left more GLP-1 receptors at the surface, so insulin release might last longer.
- What did blocking the cell's brake reveal? Researchers blocked the cell process that normally holds back insulin release. More insulin was then released after GLP-1, confirming a brake on GLP-1 action. GIP and tirzepatide gained no boost; they seemed to avoid the limit faced by GLP-1.
Coskun's earlier 2018 work included mice, so it couldn't establish patient benefit. With comparable amounts, mice ate less; their weight fell further than on GLP-1 treatment alone [1]. Phase 1 means early human tests of a drug's actions and how well people tolerate treatment. Those tests involved 142 people receiving weekly shots, with lower weight and before-food sugar than placebo, a shot without active medicine.
These experiments suggest why tirzepatide may help release insulin more effectively. Copying both hormones adds an action absent from a GLP-1 medicine alone. Keeping cells able to respond might add further benefit. Your expected weight or sugar change still needs evidence from studies of people.
What did the small human studies find about insulin?
Heise's 2022 study enrolled just 117 adults with type 2 diabetes [8]. Phase 1 means a small study of drug actions and how well people tolerate treatment. Over 28 weeks, groups received tirzepatide 15 milligrams, semaglutide 1 milligram, or placebo. Semaglutide treats diabetes and weight; placebo was a shot without active medicine.
Researchers held sugar at a set level during some tests. They also checked how the body handled an ordinary meal. The tests combined insulin release with how effectively insulin lowered sugar. A better combined result meant the body handled sugar more effectively overall.
Tirzepatide improved that combined result more than placebo [8]. The improvement was also greater than with semaglutide [8]. Insulin release improved more than on semaglutide [8]. Insulin's ability to bring sugar down improved more as well [8].
A small study can't pin down the exact size of a benefit. Researchers allowed for chance differences between groups by calculating ranges. Repeating the placebo comparison's method would cover the true difference in 95% of studies. The semaglutide comparison used the same 95% method, which doesn't count the share of patients helped.
Meal tests found smaller rises and falls in insulin and glucagon [8]. Glucagon is a hormone prompting the liver to put stored sugar into the blood. Heise's 2024 follow-up also found improvements in both insulin release and use [9]. Thomas's 2023 SURPASS-1 study found similar improvements with tirzepatide taken alone [10].
Hamamoto's 2025 work included 636 Japanese patients with diabetes. At week 52, all three amounts improved insulin tests more than dulaglutide, another diabetes medicine [19]. Before meals, insulin and a protein released alongside insulin both fell. Those lower readings suggest less insulin was needed as insulin became more effective in the body.
That doesn't conflict with releasing more insulin after food raises sugar. One finding concerns insulin needed before eating; the other concerns responding to a meal. The pancreas makes insulin and can then meet different demands. Blood tests support that explanation without proving every later health benefit.
Mari's 2025 review examined 2,539 adults from SURMOUNT-1 with excess weight. Some had normal sugar; others had raised sugar below the diabetes range. Both weight loss and treatment were linked to improvements in both insulin release and use [20]. Some improvement in insulin release appeared separate from the weight lost.
That suggests direct help for the pancreas, though weight loss also matters. The trials compared added GIP action with GLP-1 action alone. They support a benefit beyond GLP-1 alone, within the treatments tested. They didn't compare every GLP-1 medicine or every possible plan for you.
How might slower food passage and less hunger help?
Insulin isn't the only way the medicine might change your sugar readings. Researchers also tested a sugar-raising hormone and the passage of food. Some findings came from patients; others came from mice. Those limits matter before turning an explanation into a claim about you.
Less sugar released by the liver: Heise's 2022 meal tests found smaller glucagon swings than with semaglutide, another diabetes medicine [8]. The hormone glucagon prompts the liver to put stored sugar into the blood. Less excess glucagon can therefore mean less sugar entering the blood.
Food leaving the stomach more slowly: Urva's 2020 study found a delay similar to medicines copying GLP-1, a gut hormone [21]. The slowing faded with continued treatment. Slower food passage can soften the rise in sugar following meals and extend fullness.
Less eating: At comparable amounts, tirzepatide caused mice to eat less than a GLP-1 medicine [1]. People in the larger trials also often described less appetite. Researchers are still studying how GIP and GLP-1 actions in the brain affect hunger.
Together with improvements in both insulin release and use, these findings offer possible explanations. Trials in SURPASS and SURMOUNT measured actual changes in sugar and weight. Those patient results give firmer evidence than a theory about hunger alone. Your result can't be promised by a likely explanation of how treatment works.